Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease Patients

Status:
Not yet recruiting

Trial end date:
2026-03-31

Target enrollment:

Participant gender:

This study will explore the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of KP405 as a potential new treatment for Parkinson's disease.

Early Phase 1

Kariya Pharmaceuticals